- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Oral fluvoxamine and inhaled budesonide combo significantly Cuts Severe Disease in COVID-19
Researchers have found in a randomized controlled trial that treatment with oral antidepressant fluvoxamine plus inhaled budesonide among high-risk outpatients with early COVID-19 reduced the incidence of severe disease requiring advanced care. Previous studies evaluated these drugs independently. The combined effect seems to offer benefits over individual use of each drug. The findings are published in Annals of Internal Medicine.
Researchers for the TOGETHER trial, a randomized adaptive platform trial to investigate the efficacy of repurposed treatments, conducted the trial with 738 symptomatic adults with confirmed SARS-CoV-2 infection residing in a highly vaccinated population. All patients had known risk factors for progression to severe disease. The investigators randomly assigned participants to either fluvoxamine (100 mg twice daily for 10 days) plus inhaled budesonide (800 mcg twice daily for 10 days) or matching placebos over 28 days and monitored for hospitalization and/or clinical progression. They found that administration of the drug combination significantly reduced the rate of COVID-19 progression resulting in prolonged observation in an emergency setting or hospitalization.
The study authors note that theirs is among the first to evaluate a drug combination for treatment of ambulatory patients with COVID-19 in a randomized trial. A difference from prior trials is that Their trial was conducted in a population that was approximately 95% vaccinated. Given the safety, tolerability, ease of use, low cost, and widespread availability of these drugs, the researchers suggest that their findings may be useful for clinicians worldwide who are considering treating outpatients.
Reference:
Gilmar Reis, Eduardo Augusto dos Santos Moreira Silva, Daniela Carla Medeiros Silva, Lehana Thabane, Vitoria Helena de Souza Campos, Thiago Santiago Ferreira, Castilho Vitor Quirino dos Santos, Ana Maria Ribeiro Nogueira, Ana Paula Figueiredo Guimaraes Almeida, Leonardo Cançado Monteiro Savassi, Adhemar Dias de Figueiredo Neto, Nicole Ezer, Todd C. Lee, Emily Gibson McDonald, Mona Bafadhel, Christopher Butler, Josue Rodrigues Silva, Mark Dybul, and Edward J. Mills, https://doi.org/10.7326/M22-3305.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751